Select Language

MHC Clase I Servicio personalizado complejo

The core function of the immune system is to identify self, eliminate non-self, maintain normal physiological activities, and prevent invasion by exogenous pathogens. This function is largely mediated by Major Histocompatibility Complex (MHC) molecules, also known as Human Leukocyte Antigen (HLA) in humans. MHC molecules are primarily divided into two classes: MHC-I and MHC-II. MHC-I molecules are found on the surface of almost all nucleated cells and play a crucial role in presenting antigens to CD8+ T cells (cytotoxic T cells). CD8+ T cells can only recognize antigens bound to MHC-I molecules, which are mostly endogenous cellular antigens. In contrast, MHC-II molecules are more limited in distribution and are mainly expressed on antigen-presenting cells such as B cells, monocytes-macrophages, and dendritic cells. The primary function of MHC-II molecules is to present processed antigen fragments to CD4+ T cells, predominantly participating in the presentation of exogenous antigens during the initiation of immune responses.

The T cell receptor (TCR) expressed on T cells can specifically recognize complexes of MHC molecules and peptide fragments and bind to them, which is closely related to immune responses and disease resistance. For example, cytotoxic T lymphocytes (CTLs) with antigen-specificity mainly recognize endogenous antigen peptides bound to MHC-I molecules. Cytotoxic T lymphocytes (CTLs) recognize and bind specific antigenic epitopes presented within the peptide-binding groove of MHC class I molecules on the surface of target cells through their T cell receptors (TCRs). With the assistance of co-stimulatory signals, CTLs are activated, proliferate, and form epitope-specific T cell clones. Activated CTLs then engage target cells through the same mechanism to exert their physiological effects.

Download our MHC product brochure

Based on the principle of TCR recognition of MHC-peptide complexes, various related drugs have been developed, including TCR-T cell therapy, TCR protein drugs, TCR-like antibodies, and others. To better support MHC-related research, ACROBiosystems relies on their mature protein structure design platform alongside their eukaryotic protein expression technology platform to avoid any prokaryotic refolding process instabilities, incorrect complex conformations, and other issues. Using these platforms, we successfully developed a series of natural MHC complexes with high biological activity in both monomer, tetramer forms with various fluorescent labels available. This includes targets such as NY-ESO-1, WT-1, GP100, GPC, and many others. Furthermore, to meet the diverse needs of our customers, we also offer custom MHC-peptide complex development services using our technology platforms to ensure natural conformation according to your specific needs and applications.

For fluorescently labeled Peptide-MHC tetramers, we offer flexible product formats. In addition to pre-assembled ready-to-use tetramers, you can also easily assemble the desired MHC-peptide complexes by using fluorescently labeled Streptavidin with peptide-free monomers.

Click to Customize

Características del servicio

Eukaryotic expression platform for a eukaryotic-based conformation

Professional MHC-peptide complex R&D technology platform

Various types of MHC I and antigens are available

Mature bioactivity verification platform: SPR/ELISA/FACS and more

Co-expression of heterodimer results in a more natural conformation

Monomer/Tetramer forms

FITC/PE/APC/Biotin-labeled are optional

Hot Applications of MHC-peptide Complex

Early Discovery

Antigen epitope screening and validation
Specific CTL detection and analysis
TCR development and optimization

CMC Manufacturing and Quality Control

TCR development and optimization
Evaluation of specific T cell quantity, potency, and specificity

Preclinical & Clinical Research

T-cell immune monitoring
Assessment of vaccine efficacy

Lista de productos personalizados

MHC Allele
Human classical MHC class I				Human classical MHC II	Mouse	Monkey
HLA-A01:01 HLA-A02:01 HLA-A02:06 HLA-A03:01 HLA-A11:01 HLA-A24:02 HLA-A26:01 HLA-A30:01 HLA-A*33:03	HLA-B07:02 HLA-B08:01 HLA-B15:01 HLA-B15:02 HLA-B27:05 HLA-B40:01	HLA-C03:03 HLA-C03:04 HLA-C07:02:01 HLA-C08:01	HLA-E*01:03	HLA-DQA103:02&DQB103:03 HLA-DRA101:01&HLA-DRB104:01 HLA-DRA101:01&HLA-DRB111:01 HLA-DRA101:01&HLA-DRB115:01	H-2Db H-2Kb H-2Kd	Mamu-A01 Mamu-A08	New alleles are always in development. If you do not see your allele of interest, please contact us.

Antigens
AFP CLIP CMV pp65 CMV UL40 EBV EBV BRLF1 EBV BZLF-1 EBV EBNA EBV EBNA3A EBV EBNA3B EBV EBNA3C EBV LMP1 EBV LMP2 EBV LMP2A EGF R EW Glypican 3 gp100 HBV HER2 HIV Gag HPV HPV16 E7 HPV16-E6 HPV16-E7 hTERT Influenza HA InsB KRAS KRASG12A KRASG12C KRASG12D KRASG12R KRASG12S KRASG12V MAGE-A1 MAGE-A10 MAGE-A2 MAGE-A3 MAGE-A4 MBP NY-ESO-1 OVA p53 PAP PRAME PSMA RHAMM-R3 RM9 SSX-2 Survivin Survivin Mut Survivin-2B TRP1 Vaccinia virus WT-1	New antigens are always in development. If you do not see the antigen of interest, please contact us.

Antigens

AFP CLIP CMV pp65 CMV UL40 EBV EBV BRLF1 EBV BZLF-1 EBV EBNA EBV EBNA3A EBV EBNA3B EBV EBNA3C EBV LMP1 EBV LMP2 EBV LMP2A EGF R EW Glypican 3 gp100 HBV HER2 HIV Gag HPV HPV16 E7 HPV16-E6 HPV16-E7 hTERT Influenza HA InsB KRAS KRASG12A KRASG12C KRASG12D KRASG12R KRASG12S KRASG12V MAGE-A1 MAGE-A10 MAGE-A2 MAGE-A3 MAGE-A4 MBP NY-ESO-1 OVA p53 PAP PRAME PSMA RHAMM-R3 RM9 SSX-2 Survivin Survivin Mut Survivin-2B TRP1 Vaccinia virus WT-1

New antigens are always in development. If you do not see the antigen of interest, please contact us.

Click to Customize

DATOS DE ENSAYO

Bioactivity
Homogeneity
Stability
Competitive Data

Bioactivity

Cell Binding Activity – FACS, Flow Cytometry

Binding activity of PE-labelled HLA-A*02:01&B2M&NY-ESO-1 tetramers were verified using anti-NY-ESO-1 TCR-293 cells and flow cytometry. Cleanly defined populations bound with MHC tetramers were observed in comparison to negative control proteins.

PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer

Cat. No.: HL1-HP2E5

Cell Binding Activity – FACS, Flow Cytometry

PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-HP2E5) and negative control protein were first diluted in a 1:25 dilution ratio with FACS buffer. Staining was performed using 100 µL of working solution to 5e5 anti-NY-ESO-1 TCR-293 cells. Binding activity was evaluated based on PE signal intensity (QC tested).

Protocol

PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer

Cat. No.: HL1-HP2E6

PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-HP2E6) and negative control protein were first diluted in a 1:25 dilution ratio with FACS buffer. Staining was performed using 100 µL of working solution to 5e5 anti-NY-ESO-1 TCR-293 cells. Binding activity was evaluated based on PE signal intensity (QC tested).

Protocol

MHC Structure Verification – ELISA

MHC tetramers are structurally evaluated using either NY-ESO-1 specific antibodies or MHC skeleton (W6/32) targeting antibodies. Proper binding curves were observed using both antibodies, ensuring correct and natural MHC structures.

Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein with Anti-NY-ESO-1 antibodies, Human IgG1.

Cat. No.: HL1-H82E6

Immobilized Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

Protocol

Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein with Anti-HLA Class I Antibody (W6/32), Human IgG1.

Cat. No.: HL1-H82E6

Immobilized Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-1 ng/mL (Routinely tested).

Protocol

Antibody Binding Activity – SPR

MHC tetramer binding was evaluated using MHC skeleton (W6/32) targeting antibodies. Proper binding curves were observed using both antibodies, ensuring good specificity and affinity.

Human HLA-A*11:01&B2M&KRASG12D (VVGADGVGK) with Anti-HLA Class I Antibody (W6/32), Human IgG1.

Cat. No.: HLD-H52H4

Anti-HLA class I Antibody, Human IgG1 (W6/32) captured on Protein A Chip can bind Human HLA-A*11:01&B2M&KRASG12D (VVGADGVGK) Complex Protein (Cat. No. HLD-H52H4) with an affinity constant of 1.06 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol